{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:07:17Z","timestamp":1780553237294,"version":"3.54.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022335","name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PIE 13\/00040"],"award-info":[{"award-number":["PIE 13\/00040"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["FIS PI12\/00506"],"award-info":[{"award-number":["FIS PI12\/00506"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["FIS PI12\/00969"],"award-info":[{"award-number":["FIS PI12\/00969"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["RD16CIII\/0002\/0001"],"award-info":[{"award-number":["RD16CIII\/0002\/0001"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2013-44677-R"],"award-info":[{"award-number":["SAF2013-44677-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-78480-R"],"award-info":[{"award-number":["SAF2016-78480-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["BMS AI471-041"],"award-info":[{"award-number":["BMS AI471-041"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bcp.2018.08.031","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T17:57:24Z","timestamp":1534960644000},"page":"248-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"156","author":[{"given":"Mercedes","family":"Bermejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rodr\u00edguez-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosa","family":"L\u00f3pez-Huertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Coiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.08.031_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001418","article-title":"Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies","volume":"10","author":"Johnson","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: recent estimates and future implications","volume":"26","author":"Nakagawa","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.08.031_b0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2018.08.031_b0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"27+8","author":"Finzi","year":"1997","journal-title":"Science (80-)"},{"key":"10.1016\/j.bcp.2018.08.031_b0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.immuni.2017.09.014","article-title":"Transcriptional reprogramming during effector-to-memory transition renders CD4+T cells permissive for latent HIV-1 infection","volume":"47","author":"Shan","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2018.08.031_b0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.med.60.041807.123549","article-title":"Emerging concepts in the immunopathogenesis of AIDS","volume":"60","author":"Douek","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0035","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2012-11-465625","article-title":"Interleukin-7 promotes HIV persistence during antiretroviral therapy","volume":"121","author":"Vandergeeten","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2018.08.031_b0040","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.celrep.2016.02.022","article-title":"IL-7 Induces SAMHD1 phosphorylation in CD4+ T lymphocytes, improving early steps of HIV-1 life cycle","volume":"14","author":"Coiras","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2018.08.031_b0045","doi-asserted-by":"crossref","DOI":"10.2174\/1570162X14666160324125536","article-title":"HIV-1 latency and eradication: past, present and Future","volume":"14","author":"Datta","year":"2016","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/COH.0000000000000284","article-title":"Cell and gene therapy strategies to eradicate HIV reservoirs","volume":"11","author":"Spragg","year":"2016","journal-title":"Curr. Opin. HIV AIDS."},{"key":"10.1016\/j.bcp.2018.08.031_b0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ebiom.2016.04.019","article-title":"The effect of latency reversal agents on primary CD8+ T cells: implications for shock and kill strategies for human immunodeficiency virus eradication","volume":"8","author":"Walker-Sperling","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2018.08.031_b0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1742-4690-8-97","article-title":"Prolonged control of replication-competent dual-tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy","volume":"8","author":"Salgado","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2018.08.031_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2018.08.031_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"Whitney","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.031_b0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/COH.0000000000000122","article-title":"How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?","volume":"10","author":"Ananworanich","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.bcp.2018.08.031_b0080","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","article-title":"Absence of detectable HIV-1 viremia after treatment cessation in an infant","volume":"369","author":"Persaud","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0085","first-page":"1","article-title":"Very early combination antiretroviral therapy in infants: prospects for cure","author":"Rainwater-lovett","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.bcp.2018.08.031_b0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002417","article-title":"HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study","volume":"14","author":"Henrich","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0100","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"No Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2018.08.031_b0105","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1172\/JCI81400","article-title":"Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques","volume":"125","author":"Micci","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2018.08.031_b0110","unstructured":"G. Mylvaganam, S. Hicks, B. Lawson, M. Nega, V. Velu, R. Ahmed, G.J. Freeman, R.R. Amara, PD-1 Blockade as an adjunct therapy to ART and potential to destabilize siv reservoir, in: Conf. Retroviruses Opportunistic Infect., 2016, p. 93LB.v."},{"key":"10.1016\/j.bcp.2018.08.031_b0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2018.08.031_b0125","unstructured":"European Medicines Agency, European public assessment report (EPAR) for Sprycel, 2015."},{"key":"10.1016\/j.bcp.2018.08.031_b0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcp.2016.02.002","article-title":"Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells","volume":"106","author":"Bermejo","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0135","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.celrep.2013.03.017","article-title":"Phosphorylation of SAMHD1 by cyclin A2\/CDK1 regulates its restriction activity toward HIV-1","volume":"3","author":"Cribier","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2018.08.031_b0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1126\/science.286.5443.1353","article-title":"Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells","volume":"286","author":"Zhang","year":"1999","journal-title":"Science (80-)"},{"key":"10.1016\/j.bcp.2018.08.031_b0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(90)90802-L","article-title":"HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure","volume":"61","author":"Zack","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.08.031_b0150","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2013exploring the full potential of targeted therapy for CML","volume":"6","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2018.08.031_b0160","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcp.2018.08.031_b0165","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2018.08.031_b0170","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0175","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0180","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1188\/13.CJON.E13-E20","article-title":"Treating chronic myeloid leukemia: improving management through understanding of the patient experience","volume":"17","author":"Simoneau","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.bcp.2018.08.031_b0185","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/cb500116c","article-title":"Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics","volume":"9","author":"Giansanti","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2018.08.031_b0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj20030021","article-title":"Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain","volume":"372","author":"Yaqub","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2018.08.031_b0195","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR\u2013ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2018.08.031_b0200","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Dai","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.031_b0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2012.00197","article-title":"Regulation of PKC-theta function by phosphorylation in T cell receptor signaling","volume":"3","author":"Wang","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2018.08.031_b0210","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","article-title":"Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation","volume":"23","author":"Palacios","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2018.08.031_b0215","doi-asserted-by":"crossref","first-page":"27363","DOI":"10.1074\/jbc.M110.210443","article-title":"Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes","volume":"286","author":"L\u00f3pez-Huertas","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.031_b0220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcp.2015.02.009","article-title":"Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription","volume":"94","author":"Bermejo","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MCP.0b013e328338c486","article-title":"Pleural effusions due to dasatinib","volume":"16","author":"Brixey","year":"2010","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0230","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/jvi.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2018.08.031_b0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jmv.20770","article-title":"A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1","volume":"79","author":"Garcia-Perez","year":"2007","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2018.08.031_b0240","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1128\/jvi.67.11.6596-6604.1993","article-title":"Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes","volume":"67","author":"Arenzana-Seisdedos","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2018.08.031_b0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/350709a0","article-title":"HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes","volume":"350","author":"Bachelerie","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.031_b0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-1759(94)90236-4","article-title":"Determination of lymphocyte division by flow cytometry","volume":"171","author":"Lyons","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2018.08.031_b0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cell.2008.07.032","article-title":"Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication","volume":"135","author":"K\u00f6nig","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.08.031_b0260","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1084\/jem.164.1.280","article-title":"Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus","volume":"164","author":"Folks","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/87979","article-title":"A quantitative assay for HIV DNA integration in vivo","volume":"7","author":"Butler","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0270","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1128\/JVI.77.18.10119-10124.2003","article-title":"Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus","volume":"77","author":"Brussel","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2018.08.031_b0275","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JVI.80.8.3712-3720.2006","article-title":"Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex","volume":"80","author":"Dismuke","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2018.08.031_b0280","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcp.2018.08.031_b0285","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/nar\/gkq037","article-title":"Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon","volume":"38","author":"L\u00f3pez-Huertas","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ni.2236","article-title":"SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates","volume":"13","author":"Lahouassa","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2018.08.031_b0295","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from a randomized controlled trial","volume":"74","author":"Gotta","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0300","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-013-2337-0","article-title":"Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers","volume":"73","author":"Tawbi","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0305","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0310","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase i ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.031_b0320","first-page":"147","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib","volume":"54","author":"Abbas","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2018.08.031_b0325","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bcp.2018.08.031_b0330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14740338.2017.1313224","article-title":"Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection","volume":"16","author":"Coiras","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bcp.2018.08.031_b0335","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/j.1460-2075.1995.tb07141.x","article-title":"Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes","volume":"14","author":"Alcam\u00ed","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2018.08.031_b0340","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrmicro2223","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs","volume":"7","author":"Coiras","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2018.08.031_b0345","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006916","article-title":"Transcriptional and posttranscriptional regulation of HIV-1 gene expression","volume":"2","author":"Karn","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0350","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<3192::AID-IMMU3192>3.0.CO;2-E","article-title":"Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains","volume":"28","author":"Bermejo","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2018.08.031_b0355","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes","volume":"94","author":"Bleul","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2018.08.031_b0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0952-7915(92)90076-Q","article-title":"Interleukin-2","volume":"4","author":"Smith","year":"1992","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.bcp.2018.08.031_b0365","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.phrs.2007.04.009","article-title":"Protein kinase C theta (PKCtheta): a key player in T cell life and death","volume":"55","author":"Hayashi","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0370","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/384484a0","article-title":"Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation","volume":"384","author":"Yamaguchi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.031_b0375","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/518250","article-title":"Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus","volume":"195","author":"Chun","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.08.031_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033948","article-title":"Impact of multi-targeted antiretroviral treatment on gut t cell depletion and hiv reservoir seeding during acute hiv infection","volume":"7","author":"Ananworanich","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.08.031_b0385","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dks533","article-title":"Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts","volume":"68","author":"Hocqueloux","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bcp.2018.08.031_b0390","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0395","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2055-6640(20)30930-4","article-title":"HIV-infected cells are frequently clonally expanded after prolonged antiretroviral therapy : implications for HIV persistence","volume":"1","author":"Maldarelli","year":"2015","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.bcp.2018.08.031_b0400","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics","volume":"214","author":"Hosmane","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0405","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/infdis\/jiv219","article-title":"The remarkable stability of the latent reservoir for HIV-1 in resting memory CD4+ T cells","volume":"212","author":"Siliciano","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2018.08.031_b0410","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12916-015-0517-y","article-title":"HIV-1 functional cure: will the dream come true?","volume":"13","author":"Liu","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2018.08.031_b0415","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COH.0000000000000286","article-title":"Kill: Boosting HIV-specific immune responses","volume":"11","author":"Trautmann","year":"2016","journal-title":"Curr Opin HIV AIDS."},{"key":"10.1016\/j.bcp.2018.08.031_b0420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1742-4690-9-87","article-title":"SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells","volume":"9","author":"Descours","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.bcp.2018.08.031_b0425","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1074-7613(02)00481-8","article-title":"Dynamics of p56lck translocation to the T cell immunological synapse following agonist and antagonist stimulation","volume":"17","author":"Ehrlich","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2018.08.031_b0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BJ20130468","article-title":"The role of membrane rafts in Lck transport, regulation and signalling in T-cells","volume":"454","author":"Ventimiglia","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2018.08.031_b0435","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2018.08.031_b0440","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2018.08.031_b0445","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40291-016-0208-1","article-title":"Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy","volume":"20","author":"Ali","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.bcp.2018.08.031_b0455","first-page":"243","article-title":"Resistant mutations in CML and Ph+ALL \u2013 role of ponatinib","volume":"8","author":"Miller","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.bcp.2018.08.031_b0460","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1016\/j.jmb.2013.10.022","article-title":"SAMHD1 host restriction factor: A link with innate immune sensing of retrovirus infection","volume":"425","author":"Sze","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2018.08.031_b0465","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3109\/10428194.2012.656626","article-title":"Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications","volume":"53","author":"Rodriguez","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2018.08.031_b0470","series-title":"Immunomodulatory Effects of Tyrosine Kinase Inhibitors","author":"Kreutzman","year":"2013"},{"issue":"10s3","key":"10.1016\/j.bcp.2018.08.031_b0475","first-page":"55","article-title":"Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors","author":"Reinwald","year":"2015","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.bcp.2018.08.031_b0480","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1008304401661","article-title":"Acute myelogenous leukaemia and myelomonocytic blast crisis following polycythemia vera in HIV positive patients: report of cases and review of the literature","volume":"11","author":"Hentrich","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2018.08.031_b0485","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.rce.2014.01.025","article-title":"Tratamiento de la leucemia mieloide cr\u00f3nica e infecci\u00f3n por el virus de inmunodeficiencia humana","volume":"214","author":"Campillo-Recio","year":"2014","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.bcp.2018.08.031_b0490","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.leukres.2003.10.020","article-title":"Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature","volume":"28","author":"Tsimberidou","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2018.08.031_b0495","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2018.08.031_b0500","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2018.08.031_b0505","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/14787210.2017.1308823","article-title":"Potential role of tyrosine kinase inhibitors during primary HIV-1 infection","volume":"15","author":"Ambrosioni","year":"2017","journal-title":"Expert Rev. Anti. Infect. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:04:57Z","timestamp":1762095897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":100,"alternative-id":["S0006295218303575"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.031","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}